Browsing Theme 2: Population, Health & Wellness by Subject "NHE1 activity, EMPA, SGLT2, SGLT1"
Now showing items 1-1 of 1
-
The Cardiovascular Benefits of Empagliflozin, A Sodium Glucose Cotransporter Inhibitor: Is NHE1 a Viable Target?
( Qatar University Press , 2020 , Poster)Empagliflozin (EMPA), an SGLT2 inhibitor (with a low affinity for SGLT1) has attracted much attention due to a recent clinical trial, the Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG ...